Status:
RECRUITING
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Immunoglobulin A Nephropathy
Eligibility:
All Genders
18+ years
Brief Summary
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) pat...
Detailed Description
This will be a prospective, observational study. Data will be collected using the Folia Health platform. Participation in the study will occur through use of the Folia mobile platform, where study par...
Eligibility Criteria
Inclusion
- Diagnosis of IgAN, regardless of symptom or treatment history
- Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age
- US-based with a proficient understanding of and ability to read the English language
Exclusion
- None
Key Trial Info
Start Date :
March 4 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06952426
Start Date
March 4 2025
End Date
June 30 2025
Last Update
June 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigational site
Boston, Massachusetts, United States, 02108